In re Application of: Andrea Crisanti.

Application No.: 10/789,403 Filed: February 27, 2004

Page 3

Attorney Docket No.: TROJAN1100-1

## **Amendments to the Claims**

Please amend claim 1 as provided below.

Please cancel claim 5 without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Currently Amended) A conjugate comprising:
  - (a) a first region comprising the homeodomain of antennapedia-or-a functional variant thereof; and
  - (b) a second region not naturally associated with the first region; wherein the second region comprises a protein of at least 100 amino acids, and wherein at least the first region is non-denatured.
- 2. (Withdrawn) The conjugate according to claim 1, wherein the first and second regions are associated via a disulfide bond.
- 3. (Withdrawn) The conjugate according to claim 2, wherein the second region comprises an NOI.
- 4. (Original) The conjugate according to claim 1, in the form of a fusion protein.
- 5. (Canceled)
- 6. (Original) The conjugate according to claim 5, wherein the second region is a functional or regulatory protein.
- 7. (Withdrawn) The conjugate according to claim 5, wherein the second region is an antigen.

In re Application of:
Andrea Crisanti.

PATENT
Attorney Docket No.: TROJAN1100-1

Application No.: 10/789,403 Filed: February 27, 2004

Page 4

8. (Withdrawn) The conjugate according to claim 5, wherein the second region is a DNA binding domain.

- 9. (Withdrawn) The conjugate according to claim 8, wherein the second region further comprises an NOI.
- 10. (Withdrawn) The conjugate according to claim 8, wherein the second region is a histone protein.
- 11. (Withdrawn) The conjugate according to claim 1, wherein the second region comprises an NOI.
- 12. (Withdrawn) The conjugate according to claim 1, for use in an expression system.
- 13. (Original) A pharmaceutical composition comprising the conjugate of claim 1, in combination with a pharmaceutically-acceptable carrier.
- 14. (Original) The pharmaceutical composition according to claim 13, in the form of a vaccine.
- 15. (Original) A conjugate prepared by a method comprising the steps:
  - (i) culturing a host cell transformed with an expression vector comprising a nucleic acid encoding a conjugate according to claim 1 under conditions which provide for the expression of the conjugate within the host cell; and
  - (ii) recovering the conjugate by affinity purification under non-denaturing conditions.
- 16. (Original) The conjugate prepared according to claim 15, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.